Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/10/2020
SIETES contiene 93128 citas

 
 
 1 a 20 de 1155 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Samper E. Remdesivir: el culebrón de un fármaco sobrevalorado que parece acercarse a su fin. eldiario.es 2020:19 de octubre. [Ref.ID 103750]
2. Cita con resumen
Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, et al.. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020:14 de octubre. [Ref.ID 103749]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Parsons L. Researchers call on Pfizer to delay COVID-19 vaccine application . PMLiVE 2020:29 de septiembre. [Ref.ID 103748]
4.Tiene citas relacionadas Cita con resumen
Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations. N Engl J Med 2020:16 de octubre. [Ref.ID 103747]
5.Enlace a cita original Cita con resumen
WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020:15 de octubre. [Ref.ID 103745]
6. Cita con resumen
Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020:13 de octubre. [Ref.ID 103744]
7. Cita con resumen
Parsons L. Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail. PMLiVE 2020:12 de octubre. [Ref.ID 103741]
8. Cita con resumen
Parsons L. Eli Lilly’s COVID-19 antibody trial paused due to safety issue. PMLiVE 2020:14 de octubre. [Ref.ID 103740]
9. Cita con resumen
10. Cita con resumen
Logunov DY, Dolzhikova IV, Tukhvatulin AI, Shcheblyakov DV. Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply. Lancet 2020;396:3 de octubre. [Ref.ID 103738]
11.Enlace a cita original Cita con resumen
Bucci E, Andreev K, Björkman A, Calogero RA, Carafoli E, Carninci P, Castagnoli P, Cossarizza A, Musini C, Guerin P, Lipworth B, Sbardella G, Stocki T, Tuosto L, van Tulleken C, Viola A. Safety and efficacy of the Russian COVID-19 vaccine: more information needed. Lancet 2020;396:21 de septiembre. [Ref.ID 103737]
12. Cita con resumen
Parsons L. J&J halts COVID-19 vaccine study after unexplained participant illness . PMLiVE 2020:13 de octubre. [Ref.ID 103734]
13. Cita con resumen
Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2020:30 de julio. [Ref.ID 103733]
14. Cita con resumen
The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020:8 de octubre. [Ref.ID 103732]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al for the ac, et al, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 — Final report. N Engl J Med 2020:8 de octubre. [Ref.ID 103731]
16. Cita con resumen
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, et al for the mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020:29 de septiembre. [Ref.ID 103729]
18. Cita con resumen
Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, Starving H, Johansen NB, Brun NC, Hallas J, Pottegard A. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLOS Medicine 2020;17:8 de septiembre. [Ref.ID 103727]
19. Cita con resumen
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al.. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020;396:26 de septiembre. [Ref.ID 103724]
20. Cita con resumen
Pau AK, Aberg J, Baker J, Belperio S, Crew P, Gidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane C, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P, for the National Institutes of Health COVID-19 Treatment Guidelines. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2020:25 de septiembre. [Ref.ID 103723]
Seleccionar todas
 
 1 a 20 de 1155 siguiente >>